JP2005503323A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2005503323A5 JP2005503323A5 JP2002559034A JP2002559034A JP2005503323A5 JP 2005503323 A5 JP2005503323 A5 JP 2005503323A5 JP 2002559034 A JP2002559034 A JP 2002559034A JP 2002559034 A JP2002559034 A JP 2002559034A JP 2005503323 A5 JP2005503323 A5 JP 2005503323A5
- Authority
- JP
- Japan
- Prior art keywords
- pharmaceutical composition
- alkyl
- compound
- administered
- group
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000008194 pharmaceutical composition Substances 0.000 claims 67
- 150000001875 compounds Chemical class 0.000 claims 43
- 125000000217 alkyl group Chemical group 0.000 claims 35
- 229910052739 hydrogen Inorganic materials 0.000 claims 28
- 239000001257 hydrogen Substances 0.000 claims 28
- 150000002431 hydrogen Chemical class 0.000 claims 28
- 125000000547 substituted alkyl group Chemical group 0.000 claims 28
- 125000003118 aryl group Chemical group 0.000 claims 21
- 201000011510 cancer Diseases 0.000 claims 17
- 125000000753 cycloalkyl group Chemical group 0.000 claims 14
- 239000000203 mixture Substances 0.000 claims 14
- 125000003107 substituted aryl group Chemical group 0.000 claims 14
- 150000003883 epothilone derivatives Chemical class 0.000 claims 9
- 238000001990 intravenous administration Methods 0.000 claims 9
- 238000001802 infusion Methods 0.000 claims 8
- 239000000243 solution Substances 0.000 claims 8
- 239000003085 diluting agent Substances 0.000 claims 7
- 229910052736 halogen Inorganic materials 0.000 claims 7
- 150000002367 halogens Chemical class 0.000 claims 7
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims 7
- 229910052760 oxygen Inorganic materials 0.000 claims 7
- MYMOFIZGZYHOMD-UHFFFAOYSA-N oxygen Chemical compound O=O MYMOFIZGZYHOMD-UHFFFAOYSA-N 0.000 claims 7
- 239000001301 oxygen Substances 0.000 claims 7
- 150000003839 salts Chemical class 0.000 claims 7
- 239000011780 sodium chloride Substances 0.000 claims 7
- 239000012453 solvate Substances 0.000 claims 7
- NINIDFKCEFEMDL-UHFFFAOYSA-N sulfur Chemical compound [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 claims 7
- 229910052717 sulfur Inorganic materials 0.000 claims 7
- 239000011593 sulfur Substances 0.000 claims 7
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims 6
- DKGAVHZHDRPRBM-UHFFFAOYSA-N t-BuOH Chemical compound CC(C)(C)O DKGAVHZHDRPRBM-UHFFFAOYSA-N 0.000 claims 5
- 239000003814 drug Substances 0.000 claims 4
- 238000001035 drying Methods 0.000 claims 4
- 239000002736 nonionic surfactant Substances 0.000 claims 4
- 239000008389 polyethoxylated castor oil Substances 0.000 claims 4
- BPKIGYQJPYCAOW-FFJTTWKXSA-I calcium;potassium;disodium;(2S)-2-hydroxypropanoate;dichloride;dihydroxide;hydrate Chemical group O.[OH-].[OH-].[Na+].[Na+].[Cl-].[Cl-].[K+].[Ca+2].C[C@H](O)C([O-])=O BPKIGYQJPYCAOW-FFJTTWKXSA-I 0.000 claims 3
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims 3
- 238000007911 parenteral administration Methods 0.000 claims 3
- 239000004094 surface-active agent Substances 0.000 claims 3
- 206010070840 Gastrointestinal tract irritation Diseases 0.000 claims 2
- 206010022998 Irritability Diseases 0.000 claims 2
- 206010028813 Nausea Diseases 0.000 claims 2
- 206010028980 Neoplasm Diseases 0.000 claims 2
- 206010029350 Neurotoxicity Diseases 0.000 claims 2
- 239000008156 Ringer's lactate solution Substances 0.000 claims 2
- 206010044221 Toxic encephalopathy Diseases 0.000 claims 2
- 206010047700 Vomiting Diseases 0.000 claims 2
- 230000001093 anti-cancer Effects 0.000 claims 2
- 230000001387 anti-histamine Effects 0.000 claims 2
- 239000000739 antihistaminic agent Substances 0.000 claims 2
- 238000002512 chemotherapy Methods 0.000 claims 2
- 230000002887 neurotoxic Effects 0.000 claims 2
- 231100000228 neurotoxicity Toxicity 0.000 claims 2
- 238000001959 radiotherapy Methods 0.000 claims 2
- 239000002904 solvent Substances 0.000 claims 2
- 230000003442 weekly Effects 0.000 claims 2
- XOZIUKBZLSUILX-GIQCAXHBSA-N (4S,7R,8S,9S,13Z,16S)-4,8-dihydroxy-5,5,7,9,13-pentamethyl-16-[(E)-1-(2-methyl-1,3-thiazol-4-yl)prop-1-en-2-yl]-1-oxacyclohexadec-13-ene-2,6-dione Chemical group O1C(=O)C[C@H](O)C(C)(C)C(=O)[C@H](C)[C@@H](O)[C@@H](C)CCC\C(C)=C/C[C@H]1C(\C)=C\C1=CSC(C)=N1 XOZIUKBZLSUILX-GIQCAXHBSA-N 0.000 claims 1
- XLMXUUQMSMKFMH-UZRURVBFSA-N 2-hydroxyethyl (Z,12R)-12-hydroxyoctadec-9-enoate Chemical group CCCCCC[C@@H](O)C\C=C/CCCCCCCC(=O)OCCO XLMXUUQMSMKFMH-UZRURVBFSA-N 0.000 claims 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N D-Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 claims 1
- 229940093181 Glucose Injection Drugs 0.000 claims 1
- 229920002685 Polyoxyl 35CastorOil Polymers 0.000 claims 1
- 238000007865 diluting Methods 0.000 claims 1
- 239000008103 glucose Substances 0.000 claims 1
- 238000000034 method Methods 0.000 claims 1
- 238000004806 packaging method and process Methods 0.000 claims 1
- 239000000825 pharmaceutical preparation Substances 0.000 claims 1
- 239000008227 sterile water for injection Substances 0.000 claims 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N β-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US26422801P | 2001-01-25 | 2001-01-25 | |
| US29000601P | 2001-05-11 | 2001-05-11 | |
| PCT/US2002/001813 WO2002058700A1 (en) | 2001-01-25 | 2002-01-22 | Methods of administering epothilone analogs for the treatment of cancer |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2005503323A JP2005503323A (ja) | 2005-02-03 |
| JP2005503323A5 true JP2005503323A5 (zh) | 2005-12-22 |
| JP4633331B2 JP4633331B2 (ja) | 2011-02-16 |
Family
ID=26950348
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2002559034A Expired - Fee Related JP4633331B2 (ja) | 2001-01-25 | 2002-01-22 | 癌治療のためのエポチロン類似体の投与方法 |
Country Status (10)
| Country | Link |
|---|---|
| JP (1) | JP4633331B2 (zh) |
| AU (1) | AU2002245296B2 (zh) |
| CA (1) | CA2434526C (zh) |
| HR (1) | HRP20030677B1 (zh) |
| IL (1) | IL156578A0 (zh) |
| MX (1) | MXPA03006412A (zh) |
| NO (1) | NO335119B1 (zh) |
| PL (1) | PL207720B1 (zh) |
| RU (1) | RU2292202C2 (zh) |
| WO (1) | WO2002058700A1 (zh) |
Families Citing this family (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE69734362T2 (de) | 1996-12-03 | 2006-07-20 | Sloan-Kettering Institute For Cancer Research | Synthese von epothilonen, zwischenprodukte dazu, analoga und verwendungen davon |
| US6867305B2 (en) | 1996-12-03 | 2005-03-15 | Sloan-Kettering Institute For Cancer Research | Synthesis of epothilones, intermediates thereto and analogues thereof |
| US8618085B2 (en) * | 2000-04-28 | 2013-12-31 | Koasn Biosciences Incorporated | Therapeutic formulations of desoxyepothilones |
| WO2002058699A1 (en) | 2001-01-25 | 2002-08-01 | Bristol-Myers Squibb Company | Pharmaceutical forms of epothilones for oral administration |
| AU2008200555C1 (en) * | 2003-03-14 | 2011-12-15 | Novartis Ag | Treatment of proliferative diseases with epothilone derivatives and radiation |
| GB0305928D0 (en) * | 2003-03-14 | 2003-04-23 | Novartis Ag | Organic compounds |
| EP1674098A1 (en) * | 2004-12-23 | 2006-06-28 | Schering Aktiengesellschaft | Stable and tolerable parental formulations of highly reactive organic drug substances with low or no solubility in water |
| SI3002009T1 (sl) * | 2007-06-01 | 2021-09-30 | Wyeth Llc | Zdravljenje kronične mieloične levkemije, ki je odporna na imatinib, ki ima mutacijo 1457t>c na genu bcrabl, s pomočjo sestavine bosutinib |
| WO2009089138A1 (en) * | 2008-01-04 | 2009-07-16 | Bristol-Myers Squibb Company | Oral administration of ixabepilone |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TW406020B (en) * | 1993-09-29 | 2000-09-21 | Bristol Myers Squibb Co | Stabilized pharmaceutical composition and its method for preparation and stabilizing solvent |
| US5681846A (en) * | 1995-03-17 | 1997-10-28 | Board Of Regents, The University Of Texas System | Extended stability formulations for paclitaxel |
| DE69734362T2 (de) * | 1996-12-03 | 2006-07-20 | Sloan-Kettering Institute For Cancer Research | Synthese von epothilonen, zwischenprodukte dazu, analoga und verwendungen davon |
| US6605599B1 (en) * | 1997-07-08 | 2003-08-12 | Bristol-Myers Squibb Company | Epothilone derivatives |
| DE69802536T2 (de) * | 1997-07-18 | 2002-05-23 | Hewlett-Packard Co.(A Delaware Corporation), Palo Alto | Format zum informationstransfer zwischen geräten |
| US6365749B1 (en) * | 1997-12-04 | 2002-04-02 | Bristol-Myers Squibb Company | Process for the preparation of ring-opened epothilone intermediates which are useful for the preparation of epothilone analogs |
| BR9907647B1 (pt) * | 1998-02-05 | 2014-04-01 | Novartis Ag Novartis S A Novartis Inc | Formulação farmacêutica na forma de um concentrado para infusão, o qual deve ser diluído antes da administração, e solução para infusão |
| FR2775187B1 (fr) * | 1998-02-25 | 2003-02-21 | Novartis Ag | Utilisation de l'epothilone b pour la fabrication d'une preparation pharmaceutique antiproliferative et d'une composition comprenant l'epothilone b comme agent antiproliferatif in vivo |
| US6399638B1 (en) * | 1998-04-21 | 2002-06-04 | Bristol-Myers Squibb Company | 12,13-modified epothilone derivatives |
| PL349863A1 (en) * | 1999-02-18 | 2002-09-23 | Schering Ag | 16-halogen-epothilone derivatives, method for producing them and their pharmaceutical use |
| UA75365C2 (en) * | 2000-08-16 | 2006-04-17 | Bristol Myers Squibb Co | Epothilone analog polymorph modifications, a method for obtaining thereof (variants), a pharmaceutical composition based thereon |
-
2002
- 2002-01-22 MX MXPA03006412A patent/MXPA03006412A/es active IP Right Grant
- 2002-01-22 PL PL373727A patent/PL207720B1/pl unknown
- 2002-01-22 RU RU2003126170/15A patent/RU2292202C2/ru active
- 2002-01-22 IL IL15657802A patent/IL156578A0/xx not_active IP Right Cessation
- 2002-01-22 AU AU2002245296A patent/AU2002245296B2/en not_active Ceased
- 2002-01-22 WO PCT/US2002/001813 patent/WO2002058700A1/en active IP Right Grant
- 2002-01-22 JP JP2002559034A patent/JP4633331B2/ja not_active Expired - Fee Related
- 2002-01-22 CA CA2434526A patent/CA2434526C/en not_active Expired - Lifetime
-
2003
- 2003-07-24 NO NO20033341A patent/NO335119B1/no not_active IP Right Cessation
- 2003-08-25 HR HR20030677A patent/HRP20030677B1/xx not_active IP Right Cessation
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN100540006C (zh) | 铂衍生物药物制剂 | |
| CZ20003089A3 (cs) | Stabilní roztok oxiplatiny, způsob jeho přípravy, farmaceutický prostředek a použití | |
| US20080161369A1 (en) | Epothilone derivative for the treatment of hepatoma and other cancer diseases | |
| JP2017031197A (ja) | 併用療法における（＋）−１，４−ジヒドロ−７−［（３ｓ，４ｓ）−３−メトキシ−４−（メチルアミノ）−１−ピロリジニル］−４−オキソ−１−（２−チアゾリル）−１，８−ナフチリジン−３−カルボン酸の使用方法 | |
| JP2005503323A5 (zh) | ||
| JPH04505760A (ja) | Ａｚｔの副作用および毒性からの保護方法 | |
| CN115778956A (zh) | 用于治疗癌症的口服给药紫杉醇和P-gp抑制剂的治疗组合 | |
| CN108778335B (zh) | 脱环氧埃坡霉素衍生物制剂、制备及其治疗肿瘤的应用 | |
| RU2003126170A (ru) | Способы введения аналогов эпотилона при лечения рака | |
| CN101467967B (zh) | 用于静脉和脑内注射的两元溶液型制剂 | |
| JP2020533318A (ja) | ドセタキセル結合体の医薬組成物及び調製方法 | |
| JPH01156916A (ja) | 肝疾患治療剤 | |
| CN115444847A (zh) | 原小檗碱类生物碱8-氧化产物在制备降尿酸药物增效剂中的应用 | |
| JP2004536099A (ja) | チオキサンテノンから成る抗腫瘍製剤 | |
| WO2019079691A1 (en) | SMALL MOLECULES FOR THE TREATMENT OF AUTOIMMUNE DISORDERS | |
| JPS63104919A (ja) | メンタニルフエノ−ルエチレンオキサイド付加物からなる抗癌剤 |